The New Chemist’s Podcasting Group: The Path to KOLs — Interview with Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI — Co-Founder, United Theranostics

---

🎙️ In this episode of The Path to KOLs, Dr. Michael A. Morris, MD, MS, DABR, DABNM, DCI—co-founder of United Theranostics—explains how his team is moving Pluvicto from single mega-centers into safe, consistent community clinics. We dig into the toughest regulatory and logistical hurdles, the playbook for dosing accuracy, imaging quality, and safety, and how clinics are designed for a compassionate, family-centered patient journey with real-world feedback loops.

Dr. Morris also shares how United Theranostics trains local technologists, pharmacists, and nurses, mentors future KOLs, and maps a path to coverage across all 50 states. Looking ahead, we discuss what’s beyond Pluvicto—including actinium-225 PSMA approaches—and how telehealth, remote monitoring, and AI are improving patient selection, follow-up, and outcomes.

About the guest: Dr. Morris is a physician-scientist in nuclear medicine, diagnostic radiology, and clinical informatics; Medical Director in Glen Burnie, MD; adjunct faculty at the University of Miami and University of Maryland; and a principal investigator on multiple FDA clinical trials in prostate cancer and neuroendocrine tumors.

Subscribe for actionable insights at the intersection of innovation, operations, and patient-centered care.

Music by Dmitrii Kolesnikov from Pixabay

Please note: The views of this podcast reflect those of my guest(s) and I, and do not constitute in any way medical advice or consultation. Please see a board and state certified medical professional for advice, consultation and suggestions.

[Re-Aired] Mastering Science Communication with Simar Bajaj, Multi-Award-Winning Science Journalist

--

In this remixed fireside chat from 2023, we sit down with Simar Bajaj then a Harvard undergraduate student and now: a Stanford medical student, Knight-Hennessy Scholar, Oxford Marshall Scholar, and Harvard University graduate. Join us as we discuss Simar's incredible achievements in science communication, the perseverance his field demands, and the sheer hard work behind producing top-tier journalism. As a current award-winning former New York Times reporter and Forbes 30 Under 30 honoree, Simar shares invaluable insights from his experiences writing for major outlets like NPR, The Atlantic, and The Washington Post, as well as publishing first-author research in premier medical journals. This is truly a must-listen episode!

Connect with Simar:

• Website: https://www.simarbajaj.com/

• LinkedIn: https://www.linkedin.com/in/simar-bajaj/

Disclaimer:The views expressed in this podcast are those of the host and guest(s). This episode is designed to provide educational and intellectually stimulating support for peer pharmacists in training. It is not intended to serve as medical advice or recommendations. For personalized medical guidance, please consult your local board-certified physician, PA, NP, or pharmacist.

An Interview with A Mentor- Dr. Robert Langer, Sc.D. (MIT Institute Professor) on aspects of the Future of Diabetes Medicine Research

======

Diabetes therapy is entering a new phase. For decades, the central challenge was how to deliver insulin more safely, more intelligently, and more responsively.

The research work by Dr. Langer has produced a generation of technologies aimed at making therapy more autonomous: glucose-responsive insulin systems, microneedle patches, implantable rescue devices, lipid nanoparticles, and mRNA-based approaches to protein replacement.

At the same time, a separate revolution emerged from pharmacology. GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and now triple GIP/GLP-1/glucagon agonists have changed expectations for the treatment of type 2 diabetes and obesity.

=====

Music by ANDRII KORNIEV from Pixabay

====

Views of this interview reflect those of my guest and I. They don't constitute medical or professional advice. We disclaim any loss in any way.